Sign Up Now to Download a Free Research Report on
Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts
Having problems viewing PDF files? Galectin Therapeutics Inc.
Galectin Therapeutics is focused on the development of new therapies for fibrotic disease and cancer. Shares of the company surged nearly 20 percent Monday after reporting it has received a U.S. patent for a second drug class to treat chronic liver disease with fibrosis and cirrhosis.
Going forward ... (see research report)
Subscribe to News Feeds